Brivaracetam

Introduction Overview

Generic Name

brivaracetam

Brand Name

Briviact

Dosage Form

oral tablet, oral solution, intravenous injection

Drug Class

Pyrrolidine anticonvulsants

Pharmacokinetics

Absorption

Brivaracetam exhibits rapid and almost complete absorption following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug's oral bioavailability approaches 100%, and food intake does not significantly affect its absorption, allowing administration with or without food. This rapid absorption profile supports twice-daily dosing for consistent plasma levels.

Distribution

Brivaracetam displays a moderate volume of distribution, approximately 0.5 to 0.7 L/kg, indicating distribution mainly into total body water. It binds to plasma proteins at a low extent (~20%), minimizing potential displacement interactions. Brivaracetam crosses the blood-brain barrier efficiently to reach central nervous system sites of action, consistent with its anticonvulsant effect targeting synaptic vesicle protein 2A (SV2A).

Metabolism

Brivaracetam undergoes extensive metabolism in the liver primarily via hydrolysis of the acetamide group and oxidative metabolism by cytochrome P450 enzymes, mainly CYP2C19. The metabolites formed are inactive pharmacologically. Genetic polymorphisms in CYP2C19 may influence metabolism rates, but no dosage adjustment is currently recommended based on genotype. Metabolism via pathways that avoid significant involvement of CYP3A4 reduces the likelihood of interactions with medications metabolized by this enzyme.

Elimination

The elimination half-life of brivaracetam averages 7 to 8 hours, supporting twice-daily dosing. The drug and its metabolites are primarily excreted via the urine; approximately 85% of an administered dose is recovered in urine, mostly as metabolites, and less than 8% is eliminated unchanged. Brivaracetam clearance may be reduced in patients with severe hepatic impairment, necessitating dosage adjustments; renal impairment does not significantly affect drug elimination.

Dosage Forms

Adults

Briviact is administered orally as immediate-release tablets in strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, and as an oral solution formulated at 10 mg/mL concentration. Intravenous formulations available include 10 mg/mL brivaracetam solution for injection, designed for administration via intravenous infusion over 2 to 15 minutes when oral administration is temporarily not feasible. The typical adult dosing regimen starts with 50 mg orally twice daily, adjustable between 25 mg to 100 mg twice daily based on clinical response and tolerability, with a maximum daily dose of 200 mg.

Adolescents

Pediatric dosing for patients from 1 month to less than 16 years is weight-based. For children under 11 kg, the initial dose is 0.75 to 1.5 mg/kg orally twice daily, maintaining 0.75 to 3 mg/kg twice daily; for weights 11 to <20 kg, 0.5 to 1.25 mg/kg initially and 0.5 to 2.5 mg/kg maintenance twice daily; for 20 to <50 kg, 0.5 to 1 mg/kg initially with 0.5 to 2 mg/kg maintenance twice daily. For adolescents 16 years and older, adult dosing regimens apply. Briviact tablets, oral solution, and injection are interchangeable formulations for pediatric use.

Special Populations

In patients with severe hepatic impairment, dosing adjustments are recommended due to decreased clearance and increased plasma concentrations; starting with the lower end of dosing ranges is advised. No dosing adjustment is generally required in renal impairment as the kidneys primarily excrete inactive metabolites. The drug is approved for use in children as young as 1 month old, with dosing carefully titrated by weight. Geriatric patients have not shown significant pharmacokinetic differences, but dosing should follow usual clinical judgment. Intravenous administration is limited to short-term use (up to 4 consecutive days) when oral intake is not possible.

Mechanism Of Action

Brivaracetam exerts its antiepileptic activity primarily through high-affinity binding to synaptic vesicle protein 2A (SV2A), a membrane glycoprotein integral to the regulation of synaptic vesicle exocytosis in neurons. SV2A modulates neurotransmitter release, and by binding to this protein, brivaracetam modulates synaptic transmission, stabilizing neuronal excitability and preventing the abnormal neuronal firing that precipitates seizures.

The binding of brivaracetam to SV2A may influence vesicle release probability and neurotransmitter release dynamics, particularly reducing excessive excitatory neurotransmission, such as glutamate release, that contributes to seizure activity. Unlike some other anticonvulsants, brivaracetam does not significantly affect other receptors or ion channels, lending to a more targeted pharmacological profile with potentially fewer off-target effects.

At the cellular level, brivaracetam's modulation of SV2A alters neurotransmission indirectly without acting primarily on ion channels (e.g., sodium or calcium channels). This mechanism differentiates brivaracetam from older antiepileptic drugs and contributes to its efficacy in partial-onset seizures and a more favorable side effect profile. Studies have demonstrated that brivaracetam has a higher affinity and greater selectivity for SV2A compared to levetiracetam, indicating potentially enhanced potency and clinical effect.

Clinically, this unique mechanism allows brivaracetam to be effective as adjunctive therapy in partial-onset seizures with an ability to be combined with other anticonvulsants, including levetiracetam. Its rapid brain penetration and CNS selectivity underpin the clinical efficacy seen in controlled trials and practice.

Pharmacological Actions

Selective high-affinity binding to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release.
Reduction of neuronal hyperexcitability and stabilization of synaptic function.
Anticonvulsant effect in partial-onset seizures by dampening abnormal neuronal firing.
Minimal interaction with other neurotransmitter receptors or ion channels, leading to targeted action.
Rapid CNS penetration ensuring prompt therapeutic effect.
Low plasma protein binding reducing risk of displacement interactions.
Lack of induction or inhibition of major CYP enzymes reducing pharmacokinetic interactions.
Exhibits both oral and intravenous efficacy as an antiepileptic agent.

Therapeutic Clinical Uses

Adjunctive treatment of partial-onset (focal) seizures in adults.
Treatment of partial-onset seizures in children aged 1 month and older.
Management of epilepsy with focal seizures refractory to monotherapy or requiring combination treatment.
Use in patients unable to take oral medications via intravenous route for short-term therapy.
Potential for use in epilepsy syndromes characterized predominantly by partial seizures, under clinical guidance.

Side Or Adverse Effects

Somnolence (sleepiness) and fatigue are common side effects.
Dizziness and balance or coordination difficulties.
Nausea and vomiting associated with initiation in some patients.
Behavioral and psychiatric symptoms including irritability, agitation, anxiety, and mood swings.
Rare reports of psychotic symptoms such as hallucinations and delusions.
Increased risk of suicidal thoughts or behaviors; patients require monitoring, especially with prior mood disorders.
Tiredness and general malaise during dose titration or dose escalation.
Potential allergic reactions including rash, hives, and facial swelling.
Respiratory infections and nasopharyngitis reported as common adverse events in trials.
Somatic effects like headache and fatigue have been noted.

Precautions

Use cautiously in patients with a history of depression or suicidal ideation due to increased risk of psychiatric adverse events.
Monitor for new or worsening mood and behavioral symptoms during therapy.
Avoid abrupt discontinuation to prevent status epilepticus or seizure worsening.
Caution advised when operating machinery or driving until individual tolerability is established due to sedation and dizziness.
Careful assessment needed in patients with liver impairment; dose adjustments may be necessary.
Monitor closely if patient has history of substance abuse or dependence, as brivaracetam is a Schedule V controlled substance.
Evaluate risk-benefit during pregnancy and breastfeeding; seizure control is critical but fetal exposure requires caution.
Patients should be informed about signs of allergic reactions and instructed to seek immediate care if such reactions occur.
Potential for interactions requires careful review of concurrent medications.

Warnings

Suicidal ideation and behavior may be increased; prompt medical attention is needed if symptoms appear.
Potential for serious psychiatric adverse events including aggression, hostility, or psychosis.
Risk of severe allergic or hypersensitivity reactions necessitating discontinuation of therapy.
Avoid sudden withdrawal to prevent seizure exacerbation or status epilepticus.
Drowsiness and dizziness may impair the ability to perform hazardous tasks such as driving or operating machinery.
Brivaracetam is a Schedule V controlled substance; monitoring for misuse, abuse, or dependence is important.
Limited experience with intravenous use beyond 4 days; caution in prolonged parenteral administration.
Close monitoring in pediatric patients is essential given their variable dose requirements and sensitivity to psychiatric adverse effects.
Potential hepatic impairment may increase systemic exposure requiring dose modification.

Contraindications

Known hypersensitivity to brivaracetam or any component of the formulation.
Allergic reactions including anaphylaxis and angioedema to brivaracetam.
Use in children younger than 1 month old due to lack of safety and efficacy data.
Should not be administered if previous severe psychiatric reactions occurred with brivaracetam.

Drug Interactions

Rifampin significantly decreases brivaracetam plasma concentrations by induction of metabolism; dose adjustment of brivaracetam may be required.
Carbamazepine may require dose reduction when administered concomitantly due to interaction affecting carbamazepine metabolism.
Phenytoin dosage may need adjustment when co-administered with brivaracetam due to altered pharmacokinetics.
Levetiracetam co-administration shows no added therapeutic benefit but no significant pharmacokinetic interaction is observed.
Low potential for cytochrome P450 mediated drug interactions due to minor involvement of CYP2C19 pathway.
No significant interaction with oral contraceptives or other commonly prescribed medications reported.
CNS depressants may increase sedation when combined with brivaracetam; caution advised.
Careful monitoring when administered with other antiepileptic drugs due to possible additive CNS effects.

Preparations Of The Drug

Oral tablets available in 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg strengths.
Oral solution formulation at 10 mg/mL concentration with raspberry flavor for pediatric and adult dosing.
Intravenous injection solution of 10 mg/mL for intravenous infusion over 2 to 15 minutes.
Film-coated tablets designed to be swallowed whole; tablets should not be cut or crushed.
Parenteral formulation for patients unable to take oral medication temporarily, limited to 4 days use.
Tablets containing inactive ingredients including lactose monohydrate, croscarmellose sodium, magnesium stearate, and various iron oxides as colorants.
Oral solution contains sodium citrate, methylparaben, sucralose, sorbitol solution, glycerin, and raspberry flavoring agents.
Injection ingredients include sodium acetate, glacial acetic acid for pH adjustment, sodium chloride, and water for injection.